Study of Dosage Individualisation for the Treatment of Acute Myeloid Leukemia

Mikkel Krogh-Madsen23 enrolled

Overview

The present study is not hypothesis driven but will explore the ability of pharmacokinetic-pharmacodynamic modelling to predict optimal dosage of the chemotherapeutic drugs used in therapy in adult patients with acute myeloid leukemia.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Acute Myeloid Leukemia

Interventions

PK-PD analysisOTHER

The danish medicines agency regards new knowledge in pharmacokinetics and pharmacodynamics as an intervention.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * adult men and women with newly diagnosed acute myeloid leukemia Exclusion Criteria: * under age 18 years

Locations (2)

Rigshospitalet, Hematology clinic

Copenhagen, Denmark

Herlev Hospital, Hematology Clinic

Herlev, Denmark

Outcomes

Primary Outcomes

significant covariates from the PK study

Time frame: after complete analysis of data

Secondary Outcomes

Amount of the three drugs in patient plasma samples

Time frame: within 3 months of sampling

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.